Spindletop Capital

Spindletop Capital is a private equity firm based in Austin, Texas, established in 2011. The firm focuses on investing in companies within the healthcare sector, targeting areas such as healthcare services, distribution, biopharma, specialty pharmaceuticals, healthcare information technology, medical diagnostics, and medical devices. As a Registered Investment Adviser, Spindletop Capital aims to identify and support growth opportunities in these industries.

Jim Henry

Managing Director

Stephen Hipp

Managing Director

Robert McDonald MD

Operating Partner

Shannon Rothschild

Managing Director

6 past transactions

Interventional Pain Management

Private Equity Round in 2020
Address: 110 Stone Oak Pkwy, San Antonio TX 78258 Main Phone: 210-268-0129 Business Email: paindoc@sapaindoc.com Business Website: http://www.sapaindoc.com Interventional Pain Management under the guidance of Dr. Urfan Dar offers a unique approach to avoid chronic pain to maintain quality of life. Helping people alleviate back and neck pain in San Antonio and New Braunfels we are the best pain management doctors and specialists in the area. Call us today for a consultation. Services: Pain Management, Minimally Invasive Laser Spine Surgery Hours: Mon to Fri 8:00 AM to 5:00 PM , Sat & Sun : Closed Payment Methods: amex, debit, mc, discover, visa

Castle Biosciences

Venture Round in 2019
Castle Biosciences, Inc. is a commercial-stage biotechnology company headquartered in Friendswood, Texas, specializing in diagnostic and prognostic tests for dermatological cancers. The company develops innovative genomic tests to aid physicians and patients in making informed treatment decisions. Its flagship product, DecisionDx-Melanoma, is a multi-gene expression profile test designed to identify stage I and II melanoma patients at high risk of metastasis. Additionally, Castle Biosciences offers the DecisionDx-UM test, which assesses the risk of metastasis in patients with uveal melanoma, a rare eye cancer. The company is also advancing two proprietary tests aimed at addressing cutaneous squamous cell carcinoma and suspicious pigmented lesions, both of which represent significant clinical needs in dermatological oncology. Through its products, Castle Biosciences aims to provide personalized and actionable genomic information, thereby enhancing cancer diagnosis and management.

Sanova Dermatology

Acquisition in 2018
Sanova Dermatology, based in Austin, Texas, is a comprehensive dermatology center that provides both cosmetic and medical skin care services. The clinic specializes in various treatments, including wrinkle reduction, acne management, and skin cancer care. Their offerings encompass medical dermatology, surgical procedures such as Mohs micrographic surgery, and aesthetic treatments like laser procedures, dermal fillers, and Botox. With a focus on individualized care, Sanova Dermatology aims to address the unique aesthetic and medical needs of each patient through a team of experienced professionals.

HNI Healthcare

Series E in 2018
HNI Healthcare, previously known as Hospitalists Now, is a physician practice management company that leverages technology to enhance the delivery of facility-based physician services. The organization specializes in implementing full-service programs aimed at improving patient care quality through a clinically integrated care model. By focusing on value-based patient care, HNI Healthcare's platform assists hospitals and physicians in optimizing key quality and performance metrics, thereby promoting better health outcomes within healthcare facilities.

Qspex Technologies

Debt Financing in 2015
QSpex Technologies, Inc. is an optical service center based in Alpharetta, Georgia, that specializes in producing high-quality finished eyewear in the United States. Founded in 2007, the company developed a patented method for manufacturing premium lenses directly in optical offices, allowing for a cost-effective and efficient process. Utilizing advanced touchless transfer technology, QSpex enables the quick fabrication of lenses, including single vision, progressive, anti-reflective, photochromic, and polar options, with lens treatments integrated during the production process. This innovative approach allows eyewear providers to deliver finished products to patients on the same day as their eye exams. However, the company filed for voluntary liquidation under Chapter 7 in June 2020.

Qspex Technologies

Series D in 2012
QSpex Technologies, Inc. is an optical service center based in Alpharetta, Georgia, that specializes in producing high-quality finished eyewear in the United States. Founded in 2007, the company developed a patented method for manufacturing premium lenses directly in optical offices, allowing for a cost-effective and efficient process. Utilizing advanced touchless transfer technology, QSpex enables the quick fabrication of lenses, including single vision, progressive, anti-reflective, photochromic, and polar options, with lens treatments integrated during the production process. This innovative approach allows eyewear providers to deliver finished products to patients on the same day as their eye exams. However, the company filed for voluntary liquidation under Chapter 7 in June 2020.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.